- $24.42m
- $16.00m
- $3.02m
TherapeuticsMD Inc expected to post a loss of 8 cents a share - Earnings Preview
TherapeuticsMD Inc reports results for the quarter ended in December - Earnings Summary
Brief: TherapeuticsMD Announces Fourth Quarter 2021 Financial Results
TherapeuticsMD Inc expected to post a loss of 8 cents a share - Earnings Preview
TherapeuticsMD Inc expected to post a loss of 7 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Gilead, Upwork, Peabody Energy
U.S. STOCKS ON THE MOVE-Mosaic, Raytheon, Capri
U.S. STOCKS ON THE MOVE-Chevron Corp, Bluebird Bio, Uber
TherapeuticsMD rises on selling prescription service unit to GoodRx
Brief: TherapeuticsMD Enters Into A Definitive Agreement To Divest VitaCare To GoodRx
TherapeuticsMD Inc expected to post a loss of 7 cents a share - Earnings Preview
Brief: TherapeuticsMD Inc - Robert G. Finizio Notified Co Of His Decision To Resign From Board Of Directors Of Company And As Vice Chair
Brief: TherapeuticsMD Inc Appoints Hugh O’Dowd As Chief Executive Officer
TherapeuticsMD falls as FDA rejects revisions to co's birth-control drug production
Brief: U.S. Food And Drug Administration (FDA) Responds To Request From Therapeuticsmd To Revise Certain Manufacturing Testing Limits For Annovera
TherapeuticsMD rises on patent litigation settlement with Amneal
Brief: TherapeuticsMD Settles U.S. Patent Litigation with Amneal for Bijuva® — Allowing for a May 25, 2032 Generic Entry Date
TherapeuticsMD Inc reports results for the quarter ended in September - Earnings Summary
Brief: TherapeuticsMD Announces Third Quarter 2021 Financial Results